Drugs & Targets FDA to phase out animal testing requirement for monoclonal antibodies, other drugs April 18, 2025Vol.51 No.15
Drugs & Targets FDA approves Vitrakvi for NTRK gene fusion-positive solid tumors April 11, 2025Vol.51 No.14
Drugs & Targets FDA approves durvalumab for muscle invasive bladder cancer April 04, 2025Vol.51 No.13
Drugs & Targets CHMP recommends approval of Calquence plus chemoimmunotherapy for first-line mantle cell lymphoma April 04, 2025Vol.51 No.13
Drugs & Targets CHMP recommends approval for Tevimbra as a first-line treatment for extensive-stage small cell lung cancer April 04, 2025Vol.51 No.13
Drugs & Targets Exact Sciences launches the Cologuard Plus test for colorectal cancer screening April 04, 2025Vol.51 No.13
Drugs & Targets FDA approves cabozantinib for patients 12 and up with pNET and epNET March 28, 2025Vol.51 No.12
Drugs & Targets FDA approves Keytruda combination for HER2 positive gastric or gastroesophageal junction adenocarcinoma expressing PD-L1 (CPS ≥1) March 21, 2025Vol.51 No.11
